argenex (ARGX) Expected to Release Earnings on Thursday

argenex (NASDAQ:ARGX) is expected to post its Q2 2026 resultson Thursday, July 23rd. Analysts expect the company to post earnings of $5.86 per share and revenue of $1.45 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:30 AM ET.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, analysts expect argenex to post $26 EPS for the current fiscal year and $34 EPS for the next fiscal year.

argenex Stock Performance

Shares of ARGX opened at $846.19 on Tuesday. The company has a market capitalization of $52.94 billion, a price-to-earnings ratio of 37.68, a PEG ratio of 1.06 and a beta of 0.45. The company’s 50 day simple moving average is $861.63 and its 200 day simple moving average is $813.48. argenex has a 1 year low of $560.91 and a 1 year high of $953.58.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sunbelt Securities Inc. purchased a new position in shares of argenex in the 3rd quarter worth about $36,000. Geneos Wealth Management Inc. raised its holdings in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the period. Transamerica Financial Advisors LLC lifted its position in argenex by 80.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 85 shares of the company’s stock valued at $71,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in argenex by 113.1% during the second quarter. Rakuten Securities Inc. now owns 130 shares of the company’s stock valued at $72,000 after buying an additional 69 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in argenex by 60.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after buying an additional 50 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a report on Monday, June 1st. Wedbush restated an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a report on Thursday, June 11th. Morgan Stanley lifted their price objective on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Oppenheimer dropped their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a research note on Thursday, April 2nd. Finally, Guggenheim increased their target price on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, argenex has an average rating of “Moderate Buy” and an average target price of $1,037.61.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.